Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 209 | 33 | 175 |
| Samples | 199 | 28 | 170 |
| Peptides | 166 | 32 | 142 |
Function
HIST1H1D · Histone H1.3
Histone H1 protein binds to linker DNA between nucleosomes forming the macromolecular structure known as the chromatin fiber (PubMed:37922872). Histones H1 are necessary for the condensation of nucleosome chains into higher-order structured fibers and promote formation of the H3K27me3 mark by the PRC2/EED-EZH2 complex (PubMed:40516528). Together with histone H1-3, histone H1-3 acts as a regulator of splicing, most specifically exon skipping and intron retention events: histone H1-3 has a high affinity for introns and regulates splicing by affecting RNA polymerase II (RNAPII) elongation (PubMed:37922872). Also acts as a regulator of individual gene transcription through chromatin remodeling, nucleosome spacing and DNA methylation (By similarity)
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000244534 | P16402 | 209 | 166 |
Gene Properties
Recurrent Mutations
All 166 amino-acid changes on canonical ENST00000244534 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in HIST1H1D · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in HIST1H1D – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Hodgkins Lymphoma | 0/16 0% | 3/122 2% |
| Plasma Cell Myeloma | 1/44 2% | 4/305 1% |
| Endometrial Carcinoma | 0/42 0% | 8/612 1% |
| B-Cell Non-Hodgkins Lymphoma | 4/88 5% | 24/2534 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Melanoma | 1/210 0% | 16/1899 1% |
| Colorectal Carcinoma | 4/143 3% | 23/3239 1% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 8/1390 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Gastric Carcinoma | 0/74 0% | 12/1809 1% |
| Ewings Sarcoma | 0/63 0% | 2/262 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 3/810 0% |
| Cervical Carcinoma | 1/35 3% | 1/422 0% |
| Other Solid Cancers | 0/94 0% | 7/1515 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Bladder Carcinoma | 0/58 0% | 4/956 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 10/2550 0% |
| Esophageal Carcinoma | 0/23 0% | 3/769 0% |
| Ovarian Carcinoma | 2/109 2% | 1/998 0% |
| Neuroendocrine Tumour | 1/154 1% | 1/577 0% |
| Prostate Carcinoma | 0/13 0% | 5/2105 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Other Blood Cancers | 0/61 0% | 6/2725 0% |
| Non-Cancerous | 1/104 1% | 1/830 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 3/1592 0% |
| Breast Carcinoma | 0/144 0% | 6/3264 0% |
Mutation Distribution
Where HIST1H1D is mutated · all tissues, split by cell line vs tissue
How many mutations in HIST1H1D were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 45 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 209 mutations in HIST1H1D
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|